| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.29B | 2.02B | 1.90B | 1.79B | 1.68B | 1.50B |
| Gross Profit | 766.30M | 635.54M | 595.43M | 553.23M | 542.40M | 454.51M |
| EBITDA | 265.13M | 187.38M | 39.17M | -525.06M | -17.95M | 61.47M |
| Net Income | 75.46M | -10.93M | -134.52M | -662.03M | -117.04M | -57.05M |
Balance Sheet | ||||||
| Total Assets | 1.81B | 1.66B | 1.61B | 1.71B | 2.33B | 1.84B |
| Cash, Cash Equivalents and Short-Term Investments | 145.87M | 84.29M | 43.94M | 19.22M | 30.49M | 137.34M |
| Total Debt | 1.35B | 1.50B | 1.50B | 1.36B | 1.30B | 1.23B |
| Total Liabilities | 1.80B | 1.79B | 1.74B | 1.72B | 1.70B | 1.58B |
| Stockholders Equity | 9.91M | -122.09M | -127.44M | -4.17M | 637.95M | 267.17M |
Cash Flow | ||||||
| Free Cash Flow | 82.52M | 26.32M | 16.56M | -60.41M | -27.30M | 101.38M |
| Operating Cash Flow | 89.54M | 32.64M | 22.67M | -48.40M | -11.35M | 116.62M |
| Investing Cash Flow | -21.88M | -6.32M | -8.79M | -25.29M | -681.83M | -193.54M |
| Financing Cash Flow | -261.00K | 14.03M | 10.85M | 62.42M | 586.33M | 210.94M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $2.10B | 24.18 | 8.58% | ― | 18.77% | 6.88% | |
74 Outperform | $2.16B | 21.43 | 9.94% | 1.78% | 23.74% | -18.99% | |
73 Outperform | $1.03B | 38.85 | 10.87% | ― | 29.89% | 10.33% | |
70 Outperform | $1.89B | 17.53 | 5.57% | 1.64% | -22.96% | -59.35% | |
61 Neutral | $2.49B | -8.03 | -214.33% | ― | 3.93% | -42.22% | |
58 Neutral | $1.85B | 24.83 | ― | ― | 15.48% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On November 13, 2025, Aveanna Healthcare Holdings Inc. amended its Stockholders Agreement, restricting certain executives from transferring common stock without pre-approval, while allowing other stockholders to transfer shares freely. Additionally, Christopher Gordon resigned as a Class II director, and Sam Weil, a Principal at Bain Capital, was appointed to fill the vacancy, bringing his expertise in healthcare investments to the board.
On November 7, 2025, Aveanna Healthcare Holdings released a financial presentation to investors, highlighting its revenue of over $2.375 billion and an adjusted EBITDA exceeding $300 million. The presentation underscores Aveanna’s strategic use of its website for disseminating critical company information and emphasizes its strong market positioning with a diverse payor mix and no single payor contributing more than a specified percentage of revenue.
Aveanna Healthcare Holdings announced its third-quarter financial results for 2025, showing a significant improvement with a 22.2% increase in revenue to $621.9 million and a net income of $14.1 million compared to a net loss in the previous year. The company also revised its full-year 2025 revenue and Adjusted EBITDA guidance upwards, reflecting sustained business momentum and successful strategic transformations, including the integration of Thrive Skilled Pediatric Care.
On October 21, 2025, Aveanna Healthcare Holdings Inc. entered into an underwriting agreement for a secondary offering of 10,000,000 shares of common stock by certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC. The offering, which closed on October 23, 2025, was priced at $9.00 per share, with an option for underwriters to purchase an additional 1,500,000 shares. The company did not issue or sell any shares itself and did not receive any proceeds from this transaction.
On September 29, 2025, Aveanna Healthcare Holdings Inc. released a financial presentation to investors, highlighting the company’s use of its website to disseminate important information. The presentation, which is available on their website, underscores Aveanna’s commitment to transparency and timely communication with stakeholders, potentially impacting investor relations and market perception.
On September 17, 2025, Aveanna Healthcare Holdings successfully refinanced its first lien credit facility, increasing its revolving credit facility to $250 million and extending the maturity dates of its loans. This refinancing allowed Aveanna to repay its existing second lien term loans, thereby terminating the second lien term loan facility. The move strengthens Aveanna’s balance sheet, enhances liquidity, and reflects strong operational performance and confidence from financial partners, supporting the company’s strategic growth and expansion.